CHAPTER 4 84 Table 1. Baseline characteristics All (n=43) Pure (n=22) Mixed (n=21) P Age (years) 70 (49-88) 71 (49-84) 68 (51-88) 0.780 BMI (kg/m2) 27 (19-50) 26 (19-40) 28 (20-50) 0.621 CA-125 at diagnosis (IU/mL) 19 (2-508) 22 (9-508) 16 (2-175) 0.259 Follow-up (months) 34 (3-194) 22 (3-168) 41 (3-194) 0.174 Second histological component Endometrioid 16 (76) Serous 3 (14) Endometrioid + serous 2 (10) Myometrial invasion 0.393 <50% 18 (42) 8 (36) 10 (48) >50% 24 (56) 14 (64) 10 (48) Unknown 1 (2) 0 1 (5) Cervical stroma invasion 0.162 Present 18 (42) 12 (55) 6 (29) Not present 24 (56) 10 (46) 14 (67) Unknown 1 (2) 0 1 (5) Lymph nodes 0.435 Negative 17 (40) 8 (36) 9 (43) Positive pelvic nodes 4 (9) 3 (14) 1 (5) Positive para-aortal nodes 9 (21) 6 (27) 3 (14) Unknown 13 (30) 5 (23) 8 (38) FIGO stage Stage I-II 25 (58) 10 (46) 15 (71) 0.084 Stage III-IV 18 (42) 12 (55) 6 (29) Adjuvant therapy Radiotherapy 21 (51) 10 (46) 11 (52) 0.932 Chemotherapy 5 (12) 3 (14) 2 (10) Chemoradiotherapy 2 (5) 1 (5) 1 (5) None 14 (33) 8 (36) 6 (29) Unknown 1 (2) 1 (5) Residual disease Yes 9 (21) 7 (32) 2 (10) 0.072 No 34 (79) 15 (68) 19 (91) Recurrence* Yes 6 (18) 4 (27) 2 (11) 0.095 No 28 (82) 11 (73) 17 (90)
RkJQdWJsaXNoZXIy MTk4NDMw